Impact of Market Concentration in U.S. Commercial and Medicare Advantage Insurance
Recent revelations from the American Medical Association (AMA) underscore the continued heavy concentration of commercial and Medicare Advantage insurance markets in the U.S., potentially complicating negotiations for physicians seeking favorable payment terms with insurers.
The AMA study reveals that nearly half of the metropolitan regions have a single insurer wielding control over at least 50% of the market. This data, based on 2025 enrollment numbers, examines market concentration through the Herfindahl-Hirschman Index (HHI)—a tool recognized by the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) for merger assessments. Markets registering an HHI above 1,800 are deemed highly concentrated, and the study identifies that the share of highly concentrated commercial insurance markets has consistently ranged from 95% to 97% since 2014. A significant development is the average HHI increase of 87 points in recent years, with a more pronounced spike of 401 points excluding Affordable Care Act exchanges.
Key Players in Commercial Insurance
In the commercial sector, UnitedHealth Group emerges as the dominant player with a 15% market share. Following closely are CVS Health’s Aetna and Elevance Health, each holding 12% of the market. Notably, Blue Cross Blue Shield insurers collectively command 42% of the national market, with dominance across 43 states and 84% of metro areas. Such a concentration has profound implications for industry professionals as it could restrict the competitive landscape for setting premiums and service offerings.
Medicare Advantage Markets
Medicare Advantage markets tell a similar story, with 97% of metro areas classified as highly concentrated by 2025. UnitedHealth Group retains a stronghold, commanding 30% of the market nationally and the largest share in 44% of metro areas. This concentration correlates with a modest increase in average Medicare Advantage market concentration in 2025 following prior declines. For insurance professionals, these dynamics are critical as they shape the competitive environment and influence strategic planning and market entry strategies.
Industry Implications and Regulatory Concerns
AMA's insights into market dominance by a few insurers indicate the existence of monopsony power, where healthcare providers encounter limited options for negotiating payment rates due to restricted insurer choices. This condition is exacerbated by practice size, with smaller practices struggling more in payment discussions. Historical antitrust actions, such as those involving Anthem-Cigna and Aetna-Humana, have stemmed from similar market data. However, current industry trends lean towards vertical integration strategies with less antitrust scrutiny, exemplified by the Aetna-CVS merger.
Despite critiques by AHIP, which suggests that other factors, such as hospital and physician group consolidations, are more responsible for cost increases, the AMA insists on the necessity for sustained regulatory oversight. This vigilance is crucial for maintaining competitive markets and safeguarding consumer interests while reducing the risk of escalating premiums and diminished care quality.
Quick Facts About Market Concentration
- UnitedHealth leads the commercial sector with a 15% market share.
- Blue Cross Blue Shield insurers represent 42% of the national market.
- In Medicare Advantage, UnitedHealth commands 30% of the market.
- Nearly 97% of metro areas have highly concentrated Medicare Advantage markets.
For those keen on understanding further implications and future trends, reviewing detailed data and market analyses available through the AMA's Competition in Healthcare Research website can offer additional insights. Regular reports from Medical Economics provide further coverage, essential for industry professionals seeking to navigate and adapt to the evolving insurance landscape.